- |||||||||| Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open, Enrollment change, Trial primary completion date: Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (clinicaltrials.gov) - Oct 14, 2016 P2, N=25, Recruiting, Trial primary completion date: Jan 2015 --> Apr 2017 Not yet recruiting --> Recruiting | N=10 --> 25 | Trial primary completion date: May 2017 --> May 2019
- |||||||||| Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Oct 11, 2016 P1, N=42, Active, not recruiting, Not yet recruiting --> Recruiting | N=10 --> 25 | Trial primary completion date: May 2017 --> May 2019 Trial primary completion date: May 2016 --> May 2017
- |||||||||| humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial primary completion date, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Aug 8, 2016 P2, N=150, Recruiting, Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Sep 2018 --> Jan 2021
- |||||||||| Leukine (sargramostim) / Partner Therap
Trial primary completion date: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - Aug 8, 2016 P2, N=40, Recruiting, Trial primary completion date: Sep 2018 --> Jan 2021 Trial primary completion date: Jun 2016 --> Dec 2016
- |||||||||| Leukine (sargramostim) / Partner Therap
Enrollment open, Trial initiation date, Trial primary completion date: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (clinicaltrials.gov) - Jul 28, 2016 P2, N=188, Recruiting, Recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Apr 2020 --> Aug 2020
- |||||||||| SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Jul 26, 2016 P1, N=9, Completed, Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Apr 2020 --> Aug 2020 Active, not recruiting --> Completed
- |||||||||| temozolomide / Generic mfg.
Enrollment closed, Enrollment change, Immunomodulating: GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) - Jul 26, 2016 P1, N=16, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 16
- |||||||||| Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's
Enrollment open, Trial initiation date, Trial primary completion date, IO biomarker: VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Jun 29, 2016 P2, N=108, Recruiting, Trial primary completion date: Mar 2016 --> Mar 2019 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Sep 2019 --> Mar 2019
- |||||||||| Leukine (sargramostim) / Partner Therap
Trial completion, Trial primary completion date: Leukine (Sargramostim) for Parkinson's Disease (clinicaltrials.gov) - May 24, 2016 P1, N=37, Completed, Initiation date: Sep 2015 --> Jun 2014 Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Jan 2016
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Enrollment open, Metastases: Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) - May 16, 2016 P2, N=27, Recruiting, Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- |||||||||| Leukine (sargramostim) / Partner Therap
Trial primary completion date, Immunomodulating: GM-CSF for Immunomodulation Following Trauma (GIFT) Study (clinicaltrials.gov) - May 5, 2016 P4, N=200, Recruiting, Trial primary completion date: Aug 2015 --> Apr 2007 Trial primary completion date: Jun 2016 --> Jun 2017
- |||||||||| humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment change, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Apr 11, 2016 P2, N=150, Recruiting, Trial primary completion date: Oct 2015 --> Feb 2019 N=42 --> 150
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
New P2 trial, Metastases: Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) - Mar 9, 2016 P2, N=27, Not yet recruiting,
- |||||||||| Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Mar 5, 2016 P2, N=70, Recruiting, Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Apr 2017
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Trial primary completion date: Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Mar 5, 2016 P1, N=40, Active, not recruiting, Trial primary completion date: Apr 2016 --> Apr 2017 Completed --> Active, not recruiting | Trial primary completion date: Aug 2012 --> Sep 2017
|